GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Pre-Tax Income

Redhill Biopharma (Redhill Biopharma) Pre-Tax Income : $11.57 Mil (TTM As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Redhill Biopharma's pretax income for the three months ended in Jun. 2023 was $0.76 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2023 was $11.57 Mil. Redhill Biopharma's pretax margin was 42.37%.

During the past 13 years, Redhill Biopharma's highest Pretax Margin was 366.80%. The lowest was -703000.00%. And the median was -308.53%.


Redhill Biopharma Pre-Tax Income Historical Data

The historical data trend for Redhill Biopharma's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Pre-Tax Income Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.30 -76.17 -97.74 -71.67 23.95

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.70 -3.73 50.24 0.76 -

Competitive Comparison of Redhill Biopharma's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Pre-Tax Income falls into.



Redhill Biopharma Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Redhill Biopharma's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-31.432+57.542+-0.367+0.094+-1.885
=23.95

Redhill Biopharma's Pretax Income for the quarter that ended in Jun. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-4.408+0+-1.926+7.095+7.7715611723761E-16
=0.76

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma  (NAS:RDHL) Pre-Tax Income Explanation

Redhill Biopharma's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=0.761/1.796
=42.37%

During the past 13 years, Redhill Biopharma's highest Pretax Margin was 366.80%. The lowest was -703000.00%. And the median was -308.53%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.